Segunda línea en cáncer de pulmón de células no - page 7

NSCLC and NIVOLUMAB

OS in Nivolumab phase 1 (3yrs FU)

•

Pts were heavily pretreated; 54% had 3–5 prior therapies

Gettinger,

J Clin Oncol

2015

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4,5,6 8,9,10,11,12,13,14,15,16,17,...41